Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancer

YEN-TING LINCHAO-CHI HOHsu, Wei-HsunWei-HsunHsuWEI-YU LIAOCHING-YAO YANGCHONG-JEN YUTZU-HSIU TSAICHIH-HSIN YANGSHANG-GIN WUMIN-SHU HSIEHCHIA-LIN HSUWu, Chia-LingChia-LingWuYEN-LIN HUANGJIN-YUAN SHIH2024-02-062024-02-0620242045-7634https://scholars.lib.ntu.edu.tw/handle/123456789/639670According to current International Association for the Study of Lung Cancer guideline, physicians may first use plasma cell-free DNA (cfDNA) methods to identify epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant mechanisms (liquid rebiopsy) for lung cancer. Tissue rebiopsy is recommended if the plasma result is negative. However, this approach has not been evaluated prospectively using next-generation sequencing (NGS).enEGFR mutation; EGFR-TKI resistance; NSCLC; next-generation sequencing[SDGs]SDG3Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first-line EGFR inhibitor resistance in lung cancerjournal article10.1002/cam4.6870381407882-s2.0-85180722464https://api.elsevier.com/content/abstract/scopus_id/85180722464